Kindred Biosciences Inc. has reached an agreement to stock Mirataz and future biopharmaceuticals at more than 420 clinics represented by the Veterinary Hospitals Association.
The South St. Paul, Minnesota, association acts as a group purchasing organization and provider of business services and continuing education for member clinics.
“Partnering with an innovative pioneer in animal medicine like KindredBio is a massive benefit for our members and the veterinary industry,” said Jeff Benson, the VHA’s executive director. “It’s a very exciting opportunity for our veterinary members, and we look forward to a long-lasting relationship with KindredBio.”
The drug developer launched its pioneer product, Mirataz (mirtazapine transdermal ointment), in July 2018. Mirataz is formulated to manage feline weight loss caused by underlying conditions such as chronic kidney disease, cancer and diabetes. In the product pipeline, the company reported, are EpoCat, for the control of non-regenerative anemia in cats, and Zimeta (dipyrone), for the control of fever in horses.
“Unintended weight loss is a significant health concern affecting millions of cats,” said Denise Bevers, president and chief operating officer of KindredBio. “With Mirataz, veterinarians now have a tool to address weight loss quickly and early.”